• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Minerva`s schizophrenia drug rejected by FDA for 2nd time

    FIERCE BIOTECH

    Minerva Neurosciences Announces Update on its NDAfor Roluperidone

    GLOBENEWSWIRE

    Minerva Neurosciences Announces the NDA Filing for Roluperidone

    GLOBENEWSWIRE

    Minerva Receives Refusal to File Letter from FDA for its NDA for Roluperidone

    GLOBENEWSWIRE

    Minerva Submits New Drug Application to FDA for Roluperidone

    GLOBENEWSWIRE

    FDA Recommends Type C Meeting for Minerva to Discuss Evidence for Roluperidone

    GLOBENEWSWIRE

    Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and year Results

    GLOBENEWSWIRE

    The FDA spells out 4 reasons why it hates Minerva’s NDA ideas

    ENDPTS

    Minerva Neurosciences’ roluperidone fails in Phase III study

    CLINICALTRIALSARENA

    Minerva suffers another CNS defeat; Eli Lilly wins OK for tau-based Alzheimer`s diagnostic

    ENDPTS

    Minerva`s Announces Completion of Patient Enrollment Ph3 Trial of Roluperidone

    EINPRESSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.